The serological detection of HE4 has been shown to have increased sensitivity and specificity in the detection of ovarian cancer compared with CA 125, which is the current gold standard serum biomarker for ovarian carcinoma (Ferraro et al., 2013; Zhen et al., 2014). This evidence concerns the gene WFDC2 and ovarian cancer.